EMPLOYMENT AGREEMENTEmployment Agreement • August 22nd, 2019 • Fibrocell Science, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 22nd, 2019 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), is entered into as of August 20, 2019 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and Sean D. Buckley (the “Executive”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 22nd, 2019 • Fibrocell Science, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 22nd, 2019 Company Industry JurisdictionThis Amended and Restated Employment Agreement (this “Agreement”), is entered into as of August 20, 2019 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and John Maslowski (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 16th, 2015 • Fibrocell Science, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledSeptember 16th, 2015 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), is entered into as of September 14, 2015 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and John Maslowski (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2015 • Fibrocell Science, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 7th, 2015 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), is entered into as of June 1, 2015 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and Michael F. Marino Esq. (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 18th, 2015 • Fibrocell Science, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledMarch 18th, 2015 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), is entered into as of March 18, 2015 (the “Effective Date”), by and between Fibrocell Science, Inc., a Delaware corporation (the “Company”), and Keith A. Goldan (the “Executive”).